Armando Orlandi, Medical Director at the Agostino Gemelli University Hospital Foundation IRCCS, shared a post on LinkedIn:
“SABCS 2025: Key General Session Highlights
Every December, San Antonio becomes the epicenter of hope for millions affected by breast cancer worldwide. The San Antonio Breast Cancer Symposium isn’t just the largest breast cancer research meeting—it’s where 11,000+ minds from over 100 countries unite with a singular mission: to transform today’s science into tomorrow’s cures.
For four days, the Henry B. González Convention Center pulses with groundbreaking discoveries, passionate debates, and the collective determination of researchers, clinicians, and advocates who refuse to accept the status quo. This is where practice-changing data first sees daylight, where paradigms shift, and where the future of breast cancer care takes shape. SABCS 2025 (December 9-12) continues this legacy.
Here are the essential General Session highlights:
HER2+ Metastatic Disease: Maintenance Evolution
HER2CLIMB-05 (GS1-01) met its primary PFS endpoint for tucatinib + trastuzumab/pertuzumab vs placebo as first-line maintenance. Key questions remain on PFS magnitude, quality of life impact, and optimal duration. Presented by Dr. Erika Hamilton.
HR+/HER2- Complexity
ASCENT-07 (GS1-10) did not meet its primary PFS endpoint (sacituzumab govitecan vs chemotherapy post-endocrine therapy). This underscores the heterogeneity of HR+ disease and need for better biomarkers. Presented by Dr. Komal Jhaveri.
AI Integration
Multimodal AI in TAILORx (GS1-09) integrates imaging, clinical, and molecular data to predict early and late recurrence. Dr. Joseph Sparano presents this step toward clinical AI implementation, though rigorous validation remains essential.
Individualized Care
Prof Matteo Lambertini presents twice:
• GS1-04: ALTTO analysis – AI vs tamoxifen in HR+/HER2+ early BC
• GS3-02: PREFER study – fertility preservation in premenopausal patients
Both address critical quality-of-life considerations in younger patients.
Evidence-Based Supportive Care
ENHANCE Trial (GS3-04): Dr. Jun Mao presents sham-controlled data on acupuncture for cancer-related cognitive difficulties—demonstrating how integrative approaches can meet rigorous scientific standards.
Tumor Microenvironment
- GS1-05: TILs and pCR in HER2+ disease (CompassHER2, Dr. Badve)
- GS1-06: Manual vs digital vs AI TILs scoring (APHINITY, Dr. Salgado)
Also Notable
- GS1-07: ctDNA in HER2+ early BC (PHERGain)
- GS2-09: LORETTA—tamoxifen without surgery for low-risk DCIS
- GS3-01: Menopausal hormone therapy in BRCA carriers
Critical Perspective
SABCS 2025 advances multiple dimensions of breast cancer care—from targeted therapy optimization to AI integration to evidence-based supportive interventions. Looking forward to thoughtful scientific discourse and careful implementation of practice-changing findings.”
Get more details on the SABCS 2025 Events.
More posts from SABCS 2025.